FDA approves Novartis's new breast cancer treatment

The Food and Drug Administration on Monday approved Novartis' experimental drug kisqali.

Kisqali is an oral drug that serves as a first-line treatment for post menopausal women with breast cancer when used in combination with letrozole, another type of breast cancer drug.

The drug slows cancer progression by limiting the over-activation of two proteins that can cause cancer cells to grow and divide too quickly, according to a news release.

More articles on supply chain:

Do PBMs disrupt patient-physician relationships? 6 thoughts
Which news channel covers high drug costs the most?
6 things keeping supply chain leaders up at night

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars